Sort   by:  
 Page size 
ProteomicsThe histone deacetylase inhibitor romidepsin sensitizes HCC to receptor tyrosine kinase inhibitors in vitro and in vivo.
Background & Aims: Histone deacetylases (HDACs) are among the most common epigenetic dysregulations found in cancer, and considered as key events in tumour development and progression. Here we explored the therapeutic effects of romidepsin, a class-I HDAC inhibitor (HDACi), alone and in combination ...
ORGANISM(S): Homo sapiens (Human) 
2025-08-04 | PXD041166 | Pride
Receptor tyrosine kinase inhibitors (rtki) Hdac inhibitor (hdaci) Hepatocellular carcinoma (hcc) Quantitative proteome 
UnknownReceptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways.
Not available
S-EPMC7114126 | biostudies-literature
UnknownAutophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.
Not available
S-EPMC5916832 | biostudies-literature
UnknownNovel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Not available
S-EPMC8308832 | biostudies-literature
UnknownEnhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors.
Not available
S-EPMC8698536 | biostudies-literature
UnknownRadiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Not available
S-EPMC8328097 | biostudies-literature
UnknownHER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.
Not available
S-EPMC10024929 | biostudies-literature
TranscriptomicsDevelopment of Resistant Tumors to Anti-angiogenic Therapy (SU 11248) via in-vivo RNAi Screen
We sought to decipher the molecular landscape of tumor resistance to continuous treatment with VEGF-receptor tyrosine kinase inhibitor (RTKi) sunitinib (SU11248, SU). To address that, we performed serial transplantation of a syngeneic LLC tumor models in C57bl6 mice using a genome-wide lentiviral sh...
ORGANISM(S): Mus musculus 
2026-09-16 | E-MTAB-6749 | biostudies-arrayexpress
UnknownSafety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Not available
S-EPMC4348698 | biostudies-literature
UnknownInhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice.
Not available
S-EPMC2846033 | biostudies-literature
Sort   by:  
 Page size